Every letter we have printed

Please keep pressing on the difference between identity confirmed and mass consistent with. They are different claims, the second is what was measured, and the first is what gets printed. A document that used the honest phrasing would lose nothing and would tell a buyer exactly what they have.

The identity section I would accept contains four things: theoretical mass, observed mass, which mass convention was used, and the instrument. Three of the four cost nothing to print. Every certificate I hold from the wider market carries one of them.

Resolving power and mass accuracy are independent and your article treats them as one virtue. A time-of-flight instrument can be well calibrated and modest in resolving power; an ion trap can resolve and drift. The two specifications answer separate questions and a report should carry both.

Steady state is reached at different times for different compounds in this class, and holding decisions made before it is reached are being made on incomplete information about that step.

Where a trial permitted a delay in escalation, the proportion who used it is reported in some papers and is an interesting number in its own right. It is closer to real practice than the nominal schedule.

Re-titration after an interruption is the question I am asked most often and the one with the least published guidance. The pharmacokinetic reasoning is straightforward: after several half-lives the exposure has gone, and resuming at the previous dose is resuming without the accommodation that produced tolerance.

Duration of the published trials is short relative to the question. Whether a plateau at month twelve is stable at month thirty-six is a question no study in this class has answered, and it is answered confidently in general discussion.

Arrival condition should be recorded by the buyer at the moment of opening, in writing, with a photograph. It takes a minute and it is the only record of that leg that will ever exist.

The customs hold is the invisible leg. A parcel detained for four days has a thermal history nobody records, and the only trace of it is a gap in the tracking that most buyers never look at.

Cake appearance carries real information about the lyophilisation and is dismissed as cosmetic. Collapse, shrinkage or a powdery residue where a solid cake was expected are all signals about the cycle, and none of them requires an instrument to see.

Bacteriostatic diluent contains a preservative and is intended for multiple withdrawals; sterile water is not. That distinction is the one thing in this whole subject that a supplier could usefully print on the box, and I have never seen it printed. Research-use material is not approved for human use in any event, and the storage physics is the same either way.

The word independent is used for two different things: independence of ownership and independence of the sample. A service can be entirely independent commercially and still be testing material the seller handed it, and readers hear the first and assume the second.

The strongest blind design I have seen anywhere involved a third party holding the purchase record, the laboratory receiving numbered tubes and the mapping opened only after all results were in. It is not expensive. It is simply organisation, and organisation is what this market lacks.

Turnaround is the specification buyers actually choose on, and it is the one that quietly sets the method. A service promising a result within days is promising a short generic gradient, because nothing else fits the queue. Price and turnaround are method disclosures in disguise.

A modest addition to your list: anything present below the detection limit. It is obvious when stated and it is routinely forgotten, because a clean spectrum reads as a clean sample. The absence of a peak is a statement about sensitivity before it is a statement about composition.

Aggregates are the other invisible class, and for a different reason: they do not survive the ionisation. A sample that is substantially aggregated can give an entirely clean monomer spectrum, because the instrument is reporting on what made it into the gas phase.

The reasons people give at the time and the reasons they give a year later are not the same. Retrospective accounts are tidier and more causal, and any dataset assembled after the fact should be read with that in mind.

Reasons cluster by phase. Early discontinuation is dominated by tolerability, late discontinuation by cost and circumstance, and reporting them as a single distribution loses the only structure in the data.

A long half-life means every stop is a taper in pharmacokinetic terms, whether or not the dose is stepped down. The concentration declines over weeks regardless, which is a point worth making before any discussion of tapering schedules.

A note on presentation. Where a value is below the limit of detection, the report should give the detection limit, because "not detected" with a high limit and "not detected" with a low one are very different statements.

What I would like to see published is simply the proportion of suppliers who offer the test as a paid extra. It is a fact somebody could establish in a fortnight of correspondence, and it would tell readers where the market actually stands.

Price competition selects against anything that adds cost without being visible to the buyer at the point of decision. Everything discussed in this piece falls into that category, which is why none of it is offered.

You write that recombinant factor C is insensitive to the glucan branch of the cascade. It would be worth adding why anybody cares: cellulose filter media and certain paper wrappings shed glucans, and a laboratory that has chased a false positive through three repeat assays will never willingly go back to a reagent that responds to them.

The reporting asymmetry is worth naming. Severe events are newsworthy and mild ones are not, so the visible discussion is drawn from the tail of a distribution and read as though it described the middle.

Regulatory documents are public, detailed and readable, and they contain the tabulated safety data that news coverage summarises badly. Pointing readers at the primary document is more useful than another summary of it.

Nothing in your file addresses the social dimension, which for me was worse than the nausea. Six months of declining invitations to meals, and explaining to family why I was not eating. The tables do not have a row for that.

Incidence figures from placebo-controlled trials should always be quoted with the placebo arm beside them, and in secondary coverage they almost never are. The difference between arms is the finding; the raw proportion is not.

Maintenance is discussed almost entirely in terms of what is taken and almost never in terms of what is measured. A phase defined by stability needs a monitoring plan more than an acute phase does, and I see far less written about the second.

The population that has maintained for several years is small, self-selected and largely unstudied, and it is the population everybody is most curious about. That mismatch is the defining feature of this subject.

The analysis population in these designs is defined at randomisation, which is after the run-in has removed everybody who did not tolerate or did not respond. Every number downstream describes that filtered group and is quoted as though it described anybody.

Placebo arms in withdrawal designs are doing something unusual: they represent stopping, not never starting. Readers who carry an intuition from initiation trials will misread them, and the papers rarely spell out the difference.

A closing thought from the laboratory side. Nothing in this subject requires a supplier to spend heavily. Bioburden, water content and a documented closure specification are all inexpensive, and a company that published them would be visibly ahead of a market that publishes none of them.

What I would like next is a template. A single page a buyer can send that asks for bioburden, endotoxin, closure integrity and the monitoring trend in the supplier’s own terms. Half the difficulty in this subject is that nobody knows how to phrase the request.

Worth adding that endotoxin survives conditions that kill the organism that made it. A process can eliminate every viable cell and leave the pyrogenic material entirely intact, which is why the two tests exist separately and why passing one says nothing about the other.

Filtration removes organisms and does not remove endotoxin, which passes through a sterilising filter without difficulty. Anybody relying on a filtration step for both properties has been misinformed about the chemistry.

I read this twice, which is unusual, and the second reading was the useful one. Whatever the desk is doing with structure at the moment is working.

The most useful thing your department has published on this was the comparison of curve shapes across studies with the horizons marked. Seeing where each line stops does more for a reader’s calibration than any amount of argument about mechanism.

The published curves are almost always means with standard errors, which narrow as the sample grows and give an impression of precision about a population that says nothing about an individual. Standard deviations would be more honest and are rarely plotted.

A short interruption and a long one are not the same event and are discussed as though they were. Missing one weekly dose leaves substantial exposure in place; missing six weeks does not. The threshold is a matter of arithmetic and nobody prints it.

Insulin and C-peptide are frequently ordered without a clear question in mind, which is the general failing your panel-design section describes. Ordered to answer something specific they are informative; ordered to complete a picture they generate findings that require chasing.